CF PharmTech, Inc. has announced that its board of directors will convene on 31 August 2026 to deliberate several key agenda items, chief among them the approval and publication of the unaudited interim results for the six months ended 30 June 2026.

The meeting will also consider the declaration of an interim dividend, subject to board approval, alongside other routine corporate matters.

The board is chaired by Dr. Liang Bill Wenqing, who also serves as Executive Director and Chief Executive Officer. The current board comprises five executive directors, two non-executive directors and four independent non-executive directors.

The announcement was released in Hong Kong on 19 August 2026.